Vibecotamab ELISA Kit (DB714028)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DB714028
Description	Vibecotamab ELISA Kit (DB714028) — Quantitative sandwich ELISA for Vibecotamab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillon	Plasma, Serum
Sensibilité	0.156 μg/ml
Plage	0.31-5 μg/mL
Numéro d'accès	P26951 & P07766
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications	Vibecotamab
Noms alternatifs	XmAb14045, 2138442-13-2
Contexte	Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
Note	For Research Use Only.